Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients

Ritsuko Yoshikawa, Jun Wada, Kousuke Seiki, Takashi Matsuoka, Satoshi Miyamoto, Kenji Takahashi, Sachiko Ota, Kazuhi Taniai, Kazuyuki Hida, Minoru Yamakado, Kenichi Shikata, Yoshio Uehara, Yoshihiro Urade, Hirofumi Makino

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The presence of metabolic syndrome has been shown to be predictors of cardiovascular morbidity and mortality in patients with type 2 diabetes. In a cross-sectional clinical study, we investigated the association of metabolic syndrome with asymptomatic lacunar strokes and cardiovascular disease (CVD) and we compared its significance with urinary protein markers. Methods: We studied Japanese type 2 diabetes patients (n = 233, men = 124, women = 109). The diagnosis of metabolic syndrome was made according to WHO and International Diabetes Federation (IDF) criteria. Cardiovascular events were recorded and asymptomatic lacunar lesions were evaluated with magnetic resonance imaging (MRI). We also measured urinary levels of albumin, type IV collagen, β2-microglobulin (β2MG), N-acetyl-β-d-glucosaminidase (NAG) and lipocalin-type prostaglandin D synthase (PGDS). Results: The prevalence of metabolic syndrome is 31.3% (IDF) and 52% (WHO) in 233 patients and microalbuminuria was present in 62 subjects (26.6%). Metabolic syndrome (WHO) significantly associated with asymptomatic lacunar lesions (p = 0.035, OR = 2.854, CI 1.075-7.579), while metabolic syndrome (IDF) or urinary markers failed to associate with presence of asymptomatic lacunar lesions. The presence of metabolic syndrome or microalbuminuria did not show significant association with CVD; however, the elevation of β2MG, NAG and PGDS showed significant association with CVD. By a logistic regression analysis using urinary proteins as independent variables, the presence of higher PGDS excretion independently associated with history of CVD (p = 0.025, OR = 3.847, CI 1.180-12.545). Conclusions: In type 2 diabetes patients, the elevation of urinary PGDS secretion closely associated with cardiovascular events and may be a supplemental or additional marker to the criteria of metabolic syndrome.

Original languageEnglish
Pages (from-to)358-367
Number of pages10
JournalDiabetes Research and Clinical Practice
Volume76
Issue number3
DOIs
Publication statusPublished - Jun 2007

Fingerprint

prostaglandin R2 D-isomerase
Vascular System Injuries
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Hexosaminidases
Lipocalins
Lacunar Stroke
Collagen Type II
Albumins

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • Metabolic syndrome
  • Microalbuminuria
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. / Yoshikawa, Ritsuko; Wada, Jun; Seiki, Kousuke; Matsuoka, Takashi; Miyamoto, Satoshi; Takahashi, Kenji; Ota, Sachiko; Taniai, Kazuhi; Hida, Kazuyuki; Yamakado, Minoru; Shikata, Kenichi; Uehara, Yoshio; Urade, Yoshihiro; Makino, Hirofumi.

In: Diabetes Research and Clinical Practice, Vol. 76, No. 3, 06.2007, p. 358-367.

Research output: Contribution to journalArticle

Yoshikawa, R, Wada, J, Seiki, K, Matsuoka, T, Miyamoto, S, Takahashi, K, Ota, S, Taniai, K, Hida, K, Yamakado, M, Shikata, K, Uehara, Y, Urade, Y & Makino, H 2007, 'Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients', Diabetes Research and Clinical Practice, vol. 76, no. 3, pp. 358-367. https://doi.org/10.1016/j.diabres.2006.09.004
Yoshikawa, Ritsuko ; Wada, Jun ; Seiki, Kousuke ; Matsuoka, Takashi ; Miyamoto, Satoshi ; Takahashi, Kenji ; Ota, Sachiko ; Taniai, Kazuhi ; Hida, Kazuyuki ; Yamakado, Minoru ; Shikata, Kenichi ; Uehara, Yoshio ; Urade, Yoshihiro ; Makino, Hirofumi. / Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. In: Diabetes Research and Clinical Practice. 2007 ; Vol. 76, No. 3. pp. 358-367.
@article{617138b75cd0429fa200fbee4df89bd3,
title = "Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients",
abstract = "Background: The presence of metabolic syndrome has been shown to be predictors of cardiovascular morbidity and mortality in patients with type 2 diabetes. In a cross-sectional clinical study, we investigated the association of metabolic syndrome with asymptomatic lacunar strokes and cardiovascular disease (CVD) and we compared its significance with urinary protein markers. Methods: We studied Japanese type 2 diabetes patients (n = 233, men = 124, women = 109). The diagnosis of metabolic syndrome was made according to WHO and International Diabetes Federation (IDF) criteria. Cardiovascular events were recorded and asymptomatic lacunar lesions were evaluated with magnetic resonance imaging (MRI). We also measured urinary levels of albumin, type IV collagen, β2-microglobulin (β2MG), N-acetyl-β-d-glucosaminidase (NAG) and lipocalin-type prostaglandin D synthase (PGDS). Results: The prevalence of metabolic syndrome is 31.3{\%} (IDF) and 52{\%} (WHO) in 233 patients and microalbuminuria was present in 62 subjects (26.6{\%}). Metabolic syndrome (WHO) significantly associated with asymptomatic lacunar lesions (p = 0.035, OR = 2.854, CI 1.075-7.579), while metabolic syndrome (IDF) or urinary markers failed to associate with presence of asymptomatic lacunar lesions. The presence of metabolic syndrome or microalbuminuria did not show significant association with CVD; however, the elevation of β2MG, NAG and PGDS showed significant association with CVD. By a logistic regression analysis using urinary proteins as independent variables, the presence of higher PGDS excretion independently associated with history of CVD (p = 0.025, OR = 3.847, CI 1.180-12.545). Conclusions: In type 2 diabetes patients, the elevation of urinary PGDS secretion closely associated with cardiovascular events and may be a supplemental or additional marker to the criteria of metabolic syndrome.",
keywords = "Atherosclerosis, Cardiovascular disease, Metabolic syndrome, Microalbuminuria, Type 2 diabetes",
author = "Ritsuko Yoshikawa and Jun Wada and Kousuke Seiki and Takashi Matsuoka and Satoshi Miyamoto and Kenji Takahashi and Sachiko Ota and Kazuhi Taniai and Kazuyuki Hida and Minoru Yamakado and Kenichi Shikata and Yoshio Uehara and Yoshihiro Urade and Hirofumi Makino",
year = "2007",
month = "6",
doi = "10.1016/j.diabres.2006.09.004",
language = "English",
volume = "76",
pages = "358--367",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients

AU - Yoshikawa, Ritsuko

AU - Wada, Jun

AU - Seiki, Kousuke

AU - Matsuoka, Takashi

AU - Miyamoto, Satoshi

AU - Takahashi, Kenji

AU - Ota, Sachiko

AU - Taniai, Kazuhi

AU - Hida, Kazuyuki

AU - Yamakado, Minoru

AU - Shikata, Kenichi

AU - Uehara, Yoshio

AU - Urade, Yoshihiro

AU - Makino, Hirofumi

PY - 2007/6

Y1 - 2007/6

N2 - Background: The presence of metabolic syndrome has been shown to be predictors of cardiovascular morbidity and mortality in patients with type 2 diabetes. In a cross-sectional clinical study, we investigated the association of metabolic syndrome with asymptomatic lacunar strokes and cardiovascular disease (CVD) and we compared its significance with urinary protein markers. Methods: We studied Japanese type 2 diabetes patients (n = 233, men = 124, women = 109). The diagnosis of metabolic syndrome was made according to WHO and International Diabetes Federation (IDF) criteria. Cardiovascular events were recorded and asymptomatic lacunar lesions were evaluated with magnetic resonance imaging (MRI). We also measured urinary levels of albumin, type IV collagen, β2-microglobulin (β2MG), N-acetyl-β-d-glucosaminidase (NAG) and lipocalin-type prostaglandin D synthase (PGDS). Results: The prevalence of metabolic syndrome is 31.3% (IDF) and 52% (WHO) in 233 patients and microalbuminuria was present in 62 subjects (26.6%). Metabolic syndrome (WHO) significantly associated with asymptomatic lacunar lesions (p = 0.035, OR = 2.854, CI 1.075-7.579), while metabolic syndrome (IDF) or urinary markers failed to associate with presence of asymptomatic lacunar lesions. The presence of metabolic syndrome or microalbuminuria did not show significant association with CVD; however, the elevation of β2MG, NAG and PGDS showed significant association with CVD. By a logistic regression analysis using urinary proteins as independent variables, the presence of higher PGDS excretion independently associated with history of CVD (p = 0.025, OR = 3.847, CI 1.180-12.545). Conclusions: In type 2 diabetes patients, the elevation of urinary PGDS secretion closely associated with cardiovascular events and may be a supplemental or additional marker to the criteria of metabolic syndrome.

AB - Background: The presence of metabolic syndrome has been shown to be predictors of cardiovascular morbidity and mortality in patients with type 2 diabetes. In a cross-sectional clinical study, we investigated the association of metabolic syndrome with asymptomatic lacunar strokes and cardiovascular disease (CVD) and we compared its significance with urinary protein markers. Methods: We studied Japanese type 2 diabetes patients (n = 233, men = 124, women = 109). The diagnosis of metabolic syndrome was made according to WHO and International Diabetes Federation (IDF) criteria. Cardiovascular events were recorded and asymptomatic lacunar lesions were evaluated with magnetic resonance imaging (MRI). We also measured urinary levels of albumin, type IV collagen, β2-microglobulin (β2MG), N-acetyl-β-d-glucosaminidase (NAG) and lipocalin-type prostaglandin D synthase (PGDS). Results: The prevalence of metabolic syndrome is 31.3% (IDF) and 52% (WHO) in 233 patients and microalbuminuria was present in 62 subjects (26.6%). Metabolic syndrome (WHO) significantly associated with asymptomatic lacunar lesions (p = 0.035, OR = 2.854, CI 1.075-7.579), while metabolic syndrome (IDF) or urinary markers failed to associate with presence of asymptomatic lacunar lesions. The presence of metabolic syndrome or microalbuminuria did not show significant association with CVD; however, the elevation of β2MG, NAG and PGDS showed significant association with CVD. By a logistic regression analysis using urinary proteins as independent variables, the presence of higher PGDS excretion independently associated with history of CVD (p = 0.025, OR = 3.847, CI 1.180-12.545). Conclusions: In type 2 diabetes patients, the elevation of urinary PGDS secretion closely associated with cardiovascular events and may be a supplemental or additional marker to the criteria of metabolic syndrome.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Metabolic syndrome

KW - Microalbuminuria

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33947607351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947607351&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2006.09.004

DO - 10.1016/j.diabres.2006.09.004

M3 - Article

VL - 76

SP - 358

EP - 367

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -